Rapamycin in transplantation: A review of the evidence

Slides:

Advertisements

Similar presentations

TM RAPAMUNE ® O-1 RAPAMUNE ® Overview John F. Neylan, MD Vice President, Transplantation Immunology Clinical Research and Development Wyeth-Ayerst Research.

Advertisements

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Ischemic heart disease after renal transplantation

Volume 56, Issue 4, Pages (October 1999)

Stuart Jon Spechler, Rhonda F. Souza Gastroenterology

Volume 82, Issue 1, Pages 7-8 (July 2012)

Another Piece of the p27Kip1 Puzzle

Regulation of mesangial cell proliferation

Volume 83, Issue 3, Pages (March 2013)

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig

Excitation BolsTORs Motor Neurons in ALS Mice

Do Diabetes Drugs Modify the Risk of Pancreatic Cancer?

Management of advanced renal cancer

Stuart Jon Spechler, Rhonda F. Souza Gastroenterology

Innate immunity as a driving force in renal disease

Mechanical stretch induces podocyte hypertrophy in vitro1

Molecular mechanisms of diabetic renal hypertrophy

Peter J. Nelson, Thomas O. Daniel Kidney International

Inhibition of mammalian target of rapamycin: Two goals with one shot?

Volume 58, Issue 1, Pages (July 2000)

FGFR Signaling as a Target for Lung Cancer Therapy

Volume 152, Issue 1, (January 2013)

Volume 77, Issue 1, Pages 5-6 (January 2010)

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

Volume 86, Issue 2, Pages (August 2014)

Arati Khanna-Gupta Experimental Hematology

Valder R Arruda, Patricia Favaro, Jonathan D Finn Molecular Therapy

Cell cycle regulatory proteins in glomerular disease

Volume 88, Issue 4, Pages (October 2015)

David Del Bello, Michael J. Ross, Shirish S. Huprikar

Blood pressure targets in hemodialysis patients

Infected glomerulus Kidney International

Fructose intake as a risk factor for kidney stone disease

Volume 84, Issue 4, Pages (October 2013)

Volume 68, Issue 6, Pages (December 2005)

Low oxygen stimulates the immune system

Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation? Lionel Rostaing, Nassim Kamar Kidney International

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 74, Issue 8, Pages (October 2008)

Volume 85, Issue 1, Pages 3-4 (January 2014)

Edward J. Weinman, Deborah Steplock, Shirish Shenolikar

Volume 67, Issue 6, Pages (June 2005)

Nephrology Crossword: Glomerulonephritis

Volume 61, Issue 2, Pages (February 2002)

Volume 60, Issue 2, Pages (August 2001)

Volume 82, Issue 9, Pages (November 2012)

Volume 69, Issue 11, Pages (June 2006)

Volume 81, Issue 1, Pages 7-9 (January 2012)

Regulation of the G1/S transition phase in mesangial cells by E2F1

Jinhua Tang, Na Liu, Shougang Zhuang Kidney International

Organ transplantation goes to the movies

Molecular mechanisms of renal hypertrophy: Role of p27Kip1

Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn Kidney International

Is it the low-protein diet or simply the salt restriction?

Is complement a target for therapy in renal disease?

David A. Ferenbach, David C. Kluth, Jeremy Hughes Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 70, Issue 5, Pages (September 2006)

Ischemic heart disease after renal transplantation

Hisataka Kobayashi, Peter L. Choyke Kidney International

The international realities of live donor kidney transplantation

Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing Richard A.F. Clark,

Volume 57, Issue 2, Pages (October 2000)

All Roads Lead to the Ribosome

Volume 25, Issue 2, Pages (January 2007)

Volume 56, Issue 4, Pages (October 1999)

Volume 148, Issue 1, (January 2012)

Presentation transcript:

Rapamycin in transplantation: A review of the evidence Richard N. Saunders, Mathew S. Metcalfe, Michael L. Nicholson Kidney International Volume 59, Issue 1, Pages 3-16 (January 2001) DOI: 10.1046/j.1523-1755.2001.00460.x Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 Proposed mechanism of action for rapamycin. Abbreviations are: mTOR, mammalian target of rapamycin; IL, interleukin. Rapa inhibits (1) Phosphorylation of 4E-BP1, preventing release of eIF-4E and initiation of translation12,13; (2) P27-mediated activation of cdk2-cyclin E and synthesis of proteins important for cell cycle progression14; and (3) p70S6 kinase activation, limiting ribosomal protein S6 phosphorylation and reducing synthesis of ribosomal/translational proteins15,16. Kidney International 2001 59, 3-16DOI: (10.1046/j.1523-1755.2001.00460.x) Copyright © 2001 International Society of Nephrology Terms and Conditions